{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T09:41:15Z","timestamp":1768902075221,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Janssen Global Services LLC"},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s12325-022-02269-0","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T05:02:47Z","timestamp":1660107767000},"page":"4632-4644","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Effect of Guselkumab on General Health State in Biologic-Na\u00efve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial"],"prefix":"10.1007","volume":"39","clinical-trial-number":[{"clinical-trial-number":"nct03158285","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jeffrey R.","family":"Curtis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iain B.","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Proton","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feifei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasheen","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexa P.","family":"Kollmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth C.","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenglong","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie J.","family":"Shiff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May","family":"Shawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Tillett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,10]]},"reference":[{"key":"2269_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:957\u201370.","journal-title":"N Engl J Med"},{"key":"2269_CR2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.semarthrit.2017.05.010","volume":"47","author":"ME Husni","year":"2017","unstructured":"Husni ME, Merola JF, Davin S. The psychosocial burden of psoriatic arthritis. Sem Arthritis Rheum. 2017;47:351\u201360.","journal-title":"Sem Arthritis Rheum"},{"key":"2269_CR3","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Helliwell PS, Boehncke W-H, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-na\u00efve or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395:1115\u201325.","journal-title":"Lancet"},{"key":"2269_CR4","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395:1126\u201336.","journal-title":"Lancet"},{"key":"2269_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001457","volume":"7","author":"CT Ritchlin","year":"2021","unstructured":"Ritchlin CT, Helliwell PS, Boehncke W-H, et al. Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-na\u00efve or TNF\u03b1 inhibitor-experienced. RMD Open. 2021;7: e001457.","journal-title":"RMD Open"},{"key":"2269_CR6","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/art.41553","volume":"73","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through 1 year in biologic-na\u00efve patients with psoriatic arthritis. Arthritis Rheumatol. 2021;73:604\u201316.","journal-title":"Arthritis Rheumatol"},{"key":"2269_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/art.42010","volume":"74","author":"IB McInnes","year":"2022","unstructured":"McInnes IB, Rahman P, Gottlieb AB, et al. Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-na\u00efve patients with active psoriatic arthritis. Arthritis Rheum. 2022;74:475\u201385.","journal-title":"Arthritis Rheum"},{"key":"2269_CR8","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s13075-021-02554-3","volume":"23","author":"P Rahman","year":"2021","unstructured":"Rahman P, Mease PJ, Helliwell PS, et al. Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response\u2014results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis. Arthritis Res Ther. 2021;23:190.","journal-title":"Arthritis Res Ther"},{"key":"2269_CR9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group. EuroQol\u2014a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199\u2013208.","journal-title":"Health Policy"},{"key":"2269_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/00005650-200503000-00003","volume":"43","author":"JW Shaw","year":"2005","unstructured":"Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43:203\u201320.","journal-title":"Med Care"},{"key":"2269_CR11","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B Van Hout","year":"2012","unstructured":"Van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15:708\u201315.","journal-title":"Value Health"},{"key":"2269_CR12","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.23568","volume":"59","author":"PJ Healy","year":"2008","unstructured":"Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum. 2008;59:686\u201391.","journal-title":"Arthritis Rheum"},{"key":"2269_CR13","first-page":"1740","volume":"34","author":"DD Gladman","year":"2007","unstructured":"Gladman DD, Inman RD, Cook RJ, et al. International spondyloarthritis interobserver reliability exercise-the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol. 2007;34:1740\u20135.","journal-title":"J Rheumatol"},{"key":"2269_CR14","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3899\/jrheum.130163","volume":"40","author":"DD Gladman","year":"2013","unstructured":"Gladman DD, Ziouzina O, Thavaneswaran A, et al. Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era. J Rheumatol. 2013;40:1357\u20139.","journal-title":"J Rheumatol"},{"key":"2269_CR15","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000250839","volume":"157","author":"T Fredriksson","year":"1978","unstructured":"Fredriksson T, Pettersson U. Severe psoriasis\u2014oral therapy with a new retinoid. Dermatologica. 1978;157:238\u201344.","journal-title":"Dermatologica"},{"key":"2269_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/09546634.2013.865009","volume":"26","author":"RG Langley","year":"2015","unstructured":"Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator\u2019s Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatol Treat. 2015;26:23\u201331.","journal-title":"J Dermatol Treat"},{"key":"2269_CR17","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1172\/JCI200318921","volume":"111","author":"MB Pepys","year":"2003","unstructured":"Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805\u201312.","journal-title":"J Clin Invest"},{"key":"2269_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/art.1780230202","volume":"23","author":"JF Fries","year":"1980","unstructured":"Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137\u201345.","journal-title":"Arthritis Rheum"},{"key":"2269_CR19","volume-title":"SF-36 physical and mental health summary scales: a user\u2019s manual","year":"1994","unstructured":"Ware JE, Kosinski M, Keller SL, editors. SF-36 physical and mental health summary scales: a user\u2019s manual. Boston: Health Assessment Lab, New England Medical Center; 1994."},{"key":"2269_CR20","first-page":"811","volume":"32","author":"D Cella","year":"2005","unstructured":"Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol. 2005;32:811\u20139.","journal-title":"J Rheumatol"},{"key":"2269_CR21","first-page":"582","volume":"41","author":"GR Norman","year":"2003","unstructured":"Norman GR, Sloan JA, Wyrwich KW. Interpretation of change in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41:582\u201392.","journal-title":"Med Care"},{"key":"2269_CR22","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3389\/fmed.2018.00246","volume":"5","author":"YY Leung","year":"2018","unstructured":"Leung YY, Ogdie A, Orbai AM, et al. Classification and outcome measures for psoriatic arthritis. Front Med. 2018;5:246.","journal-title":"Front Med"},{"key":"2269_CR23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jval.2016.11.006","volume":"20","author":"AJ Wailoo","year":"2017","unstructured":"Wailoo AJ, Hernandez-Alava M, Manca A, et al. Mapping to estimate health-state utility from non-preference-based outcome measures: an ISPOR Good Practices for Outcomes Research Task Force report. Value Health. 2017;20:18\u201327.","journal-title":"Value Health"},{"key":"2269_CR24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10198-018-0955-5","volume":"20","author":"MF Janssen","year":"2019","unstructured":"Janssen MF, Szende A, Cabases J, Ramos-Go\u00f1i JM, Vilagut G, K\u00f6nig HH. Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries. Eur J Health Econ. 2019;20:205\u201316.","journal-title":"Eur J Health Econ"},{"key":"2269_CR25","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1136\/annrheumdis-2018-215003","volume":"78","author":"A Kavanaugh","year":"2019","unstructured":"Kavanaugh A, Gottlieb A, Morita A, et al. The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled trials. Ann Rheum Dis. 2019;78:1215\u20139.","journal-title":"Ann Rheum Dis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02269-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02269-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02269-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T02:09:57Z","timestamp":1662948597000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02269-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["2269"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02269-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,10]]},"assertion":[{"value":"16 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}